Background Though elevated lipoprotein (a) (Lp[a]) is associated with ASCVD and testing is recommended for all adults, how to use Lp(a) for decision-making in low-risk patients remains uncertain. Methods We studied low-risk adults in a large healthcare system, excluding those on statins or with statin indications in th...
K. F. Faridi, Qi-Fan Wu, E. Spatz et al.· American Heart Journal Plus:...· 0 citations
BACKGROUND
Evolocumab reduces major adverse cardiovascular events in randomized trials, but evidence of its effectiveness in real-world clinical practice remains limited.
METHODS
US adults with atherosclerotic cardiovascular disease who initiated evolocumab between 2017 and 2023 were identified from the Komodo Health...
Ran Jin, K. Hurwitz, N. Dhalwani et al.· Journal of the American Hear...· 0 citations
In a contemporary AMI cohort, combined LLT remained low at presentation and discharge despite suboptimal LDL-C, underscoring actionable gaps in ASCVD management.
Mohammed Essa, Qifan Wu, Yuan Lu et al.· JACC: Advances· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.